William J. Slichenmyer

Author

Also Known As

W J Slichenmyer, W SLICHENMYER, W Slichenmyer, W. J. Slichenmyer, W. Slichenmyer, W.J. Slichenmyer, William J Slichenmyer, William J. Slichenmyer, William Slichenmyer

Publications

2.9K

Citations

H-Index

Concepts

All Affiliations

Johns Hopkins University AVEO Oncology (United States)Zaporizhzhia Medical Academy of Post-Graduate Education Ministry of Health of Ukraine The University of Texas Health Science Center at San Antonio Covance (United States)

About

William J. Slichenmyer is an author at Johns Hopkins University specializing in medicine, oncology, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	16	17	912
2	Health Sciences	3	3	130
3	Cell Biology	2	2	350
4	Hepatology	2	2	76
5	Cellular Therapies	1	1	13

William J. Slichenmyer

Publications

1.8K

Citations

H-Index

Page 1

	Year	Citations
Loss of a p53-associated G1 checkpoint does not decrease cell survival following DNA damage. William J. Slichenmyer, William G. Nelson, Robbert J.C. Slebos, PubMed P53 FunctionGenome InstabilityDna DamageMedicineApoptosis	1993	331
Randomized Phase II Study of BR96-Doxorubicin Conjugate in Patients With Metastatic Breast Cancer Anthony W. Tolcher, Steven Sugarman, Karen A. Gelmon, Journal of Clinical Oncology	1999	267
Suramin Therapy for Patients With Symptomatic Hormone-Refractory Prostate Cancer: Results of a Randomized Phase III Trial Comparing Suramin Plus Hydrocortisone to Placebo Plus Hydrocortisone Eric J. Small, Mark Meyer, M. Ernest Marshall, Journal of Clinical Oncology	2000	188
Taxol William J. Slichenmyer, Daniel D Von Hoff Anti-Cancer Drugs New Anti-cancer DrugMedicinal ChemistryOncologyMedicinePathology	1991	153
Antitumor Activity and Safety of Tivozanib (AV-951) in a Phase II Randomized Discontinuation Trial in Patients With Renal Cell Carcinoma Dmitry Nosov, Brooke Esteves, Oleg Lipatov, Journal of Clinical Oncology	2012	126
Phase I and pharmacologic study of topotecan in patients with impaired renal function. Séamus O’Reilly, Eric K. Rowinsky, William J. Slichenmyer, Journal of Clinical Oncology	1996	116
Tivozanib versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: Results from a phase III randomized, open-label, multicenter trial. Robert J. Motzer, Dmitry Nosov, Tim Eisen, Journal of Clinical Oncology Renal PathologyJco 2011PharmacotherapyOncologyGenitourinary Cancer	2012	95
Serum Prostate-Specific Antigen Decline as a Marker of Clinical Outcome in Hormone-Refractory Prostate Cancer Patients: Association With Progression-Free Survival, Pain End Points, and Survival Eric J. Small, Alex McMillan, Mark Meyer, Journal of Clinical Oncology	2001	84
Phase I and Pharmacologic Studies of Topotecan in Patients With Impaired Hepatic Function Séamus O’Reilly, Eric K. Rowinsky, William J. Slichenmyer, JNCI Journal of the National Cancer Institute	1996	74
Randomized phase II study of ficlatuzumab (formerly AV-299), an anti-hepatocyte growth factor (HGF) monoclonal antibody (MAb) in combination with gefitinib (G) in Asian patients (pts) with NSCLC. Tony Mok, E. Tan, K. Park, Journal of Clinical Oncology ImmunologyPathologyPhase Ii StudyImmunotherapyFibroblast Growth Factor	2011	42

Page 1